Roger Jeffs, serving in a directorial capacity at Axsome Therapeutics, Inc. (NASDAQ:AXSM), recently completed the disposal of common stock valued at $141,655. According to regulatory filings, the transactions were executed over a two-day period, specifically on June 10 and June 11, 2026. The shares were liquidated at prices fluctuating between $246.18 and $249.12 per unit.
The sales were not discretionary but were structured to satisfy tax obligations linked to the vesting of Restricted Stock Units (RSUs). These equity awards were initially granted to Mr. Jeffs on June 6, 2025. The disposition of shares occurred in two equal batches: 286 shares were sold on June 10, followed by an identical quantity of 286 shares on June 11. This activity was conducted under the framework of a pre-approved 10b5-1 trading plan, which has now been fully executed. Post-transaction, Mr. Jeffs maintains a direct holding of 58,367 shares of Axsome Therapeutics common stock.
The insider transaction takes place while Axsome shares are trading in close proximity to their 52-week high of $257.44. Over the preceding year, the stock has delivered a substantial 139% return. Independent analysis from InvestingPro suggests that the current stock price may be overvalued relative to its calculated Fair Value. The analysis notes that 15 additional ProTips are available to assist investors in evaluating the company's valuation metrics and growth trajectory.
Concurrent with the insider activity, Axsome Therapeutics has reported several material developments that may influence investor sentiment. Jefferies has raised its price target for Axsome to $380, maintaining a Buy rating. This upgrade is predicated on the expectation that the peak sales for Auvelity, particularly in the treatment of major depression and Alzheimer’s agitation, could exceed $6 billion. Current data indicates that sales for Auvelity in the major depression segment alone have already surpassed $610 million.
Additionally, H.C. Wainwright has reiterated a Buy rating with a $290 price target. This action follows Axsome’s resolution of patent litigation concerning its product SUNOSI. The company settled all disputes related to Abbreviated New Drug Applications filed by entities seeking to market generic versions of SUNOSI in the United States. The resolution of these legal matters removes a significant barrier to market entry for competitors.
Beyond corporate and financial metrics, Axsome engaged in community-focused initiatives during June. The company supported Migraine and Headache Awareness Month by illuminating its headquarters in purple, aiming to raise public awareness for these conditions. Furthermore, Morgan Stanley reported a 2.9% year-over-year increase in total prescriptions within the U.S. antipsychotic market for the week ending May 29. This data point highlights broader trends in the pharmaceutical sector that may impact Axsome's operating environment.